Your browser doesn't support javascript.
loading
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial.
Kurreck, Annika; Heinemann, Volker; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Graeven, Ullrich; Heinrich, Kathrin; Held, Swantje; Stahler, Arndt; Alig, Annabel Helga Sophie; Jelas, Ivan; von Einem, Jobst C; Stintzing, Sebastian; Giessen-Jung, Clemens; Modest, Dominik P.
Afiliación
  • Kurreck A; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Tumor Immunology Charité Virchow Klinikum (CVK), Berlin, Germany.
  • Heinemann V; 2 Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, München, Germany.
  • Fischer von Weikersthal L; German Cancer Consortium (DKTK), Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.
  • Decker T; Gesundheitszentrum St. Marien, Amberg, Germany.
  • Kaiser F; Oncological Practice, Ravensburg, Germany.
  • Uhlig J; Oncological Practice, Landshut, Germany.
  • Schenk M; Oncological Practice, Naunhof, Germany.
  • Freiberg-Richter J; Department of Hematology and Oncology, Clinic "Barmherzige Brüder Regensburg", Regensburg, Germany.
  • Peuser B; Oncological Practice, Dresden, Germany.
  • Denzlinger C; Oncological Practice am Diakonissenhaus, Leipzig, Germany.
  • Graeven U; Department of Internal Medicine III (Oncology, Hematology, Palliative Care) Marienhospital, Stuttgart, Germany.
  • Heinrich K; Department of Hematology, Oncology, and Gastroenterology, Kliniken Maria Hilf GmbH, Mönchengladbach, Germany.
  • Held S; 2 Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, München, Germany.
  • Stahler A; ClinAssess GmbH, Leverkusen, Germany.
  • Alig AHS; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Tumor Immunology Campus Charité Mitte (CCM), Berlin, Germany.
  • Jelas I; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Tumor Immunology Campus Charité Mitte (CCM), Berlin, Germany.
  • von Einem JC; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Tumor Immunology Charité Virchow Klinikum (CVK), Berlin, Germany.
  • Stintzing S; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Tumor Immunology Campus Charité Mitte (CCM), Berlin, Germany.
  • Giessen-Jung C; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Tumor Immunology Campus Charité Mitte (CCM), Berlin, Germany.
  • Modest DP; 2 Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, München, Germany.
Front Oncol ; 12: 751453, 2022.
Article en En | MEDLINE | ID: mdl-35251955
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Alemania